Retinal Disorder Treatment Market Size, Share & Trends Analysis Report By Type (Macular Degeneration, Diabetic Retinopathy), By Dosage Form, By Distribution Channel, By Product Type, And Segment Forecasts, 2023 - 2030
Retinal Disorder Treatment Market Growth & Trends
The global retinal disorder treatment market size is expected to reach USD 25.69 billion, expanding at a CAGR of 9.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. Growth in the market is fueled by the increasing prevalence of retinal disorders around the world and the unmet need for affordable and efficient treatments. Furthermore, improved funding by regulatory bodies for R&D associated with ocular disorders is expected to further drive market growth.
Retinal diseases are one of the leading causes of visual impairment among the global population. According to WHO, in 2022, a near or distant vision impairment affects at least 2.2 billion people worldwide. Nearly half of these cases, or around 1 billion, involved vision impairments that either could have been avoided or are still unaddressed. Factors such as changing lifestyles, increased life expectancy, and escalating prevalence of systemic diseases like hypertension and diabetes mellitus are the most common causes of retinal disorders. This demonstrates an unmet need among retinal disorder patients for treatment of the condition.
The rising geriatric population is acting as a driver for the market; age-related macular degeneration (AMD) is one of the leading causes of vision loss in people aged over 65 years. AMD is characterized by the degeneration of an area of the retina known as the macula, which is responsible for central vision. The growing elderly population is expected to create a wider patient pool for the treatment of AMD. For instance, according to a WHO report in 2021, by 2030, 1 in every 6 people in the world will be aged 60 years or over. Furthermore, over this period of time, the population aged over 60 years is expected to increase from 1 billion in 2020 to 1.4 billion.
The high cost associated with retinal disorder treatment poses a threat to the growth of the market. However, increasing efforts from key players operating in the market for developing new products for the enhancement of their product pipeline is expected to drive the market. For instance, in January 2022, Genentech’s Vabysmo was approved by the FDA, the first-in-class bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. The launch of novel products is expected to propel market growth.
Retinal Disorder Treatment Market Report Highlights
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook